Originally published as JCO Early Release 10.1200/JCO.2006.07.5598 on November 6 2006

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kuendgen, A. Articles by Germing, U. Search for Related Content PubMed PubMed Citation Articles by Kuendgen, A. Articles by Germing, U.

Myelodysplastic Syndromes in Patients Younger Than Age 50

Andrea Kuendgen, Corinna Strupp, Manuel Aivado, Barbara Hildebrandt, Rainer Haas, Norbert Gattermann, Ulrich Germing

From the Department of Hematology, Oncology, and Clinical Immunology, and Institute of Human Genetics, Heinrich-Heine-University, Duesseldorf, Germany

Address reprint requests to Andrea Kuendgen, MD, Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University, Moorenstr 5, D-40225 Düsseldorf, Germany; e-mail: kuendgen{at}med.uni-duesseldorf.de

PURPOSE: Myelodysplastic syndromes (MDS) mainly occur in the elderly but can affect younger individuals too. The latter require special consideration to identify suitable candidates for allogeneic stem-cell transplantation, a potentially curative approach carrying a high risk of treatment-related complications.

PATIENTS AND METHODS: We report the largest series of young MDS patients as yet, including 232 patients younger than 50 years. Their clinical characteristics and prognosis are compared with 2,496 patients older than 50 years.

RESULTS: Survival was significantly longer in the younger versus older age group (40 v 23 months, respectively; P < .00005). The difference arose from patients belonging to the low- and intermediate-I–risk categories of the International Prognostic Scoring System (median survival not reached v 45 months, respectively; P < .00005). In contrast, survival was identical for both age groups (8 months for both younger and older patients; P = .81) in the intermediate-II–and high-risk categories. Established classification systems and risk scores were applicable to young patients with primary MDS. Interestingly, a particularly large difference in median survival time was seen between the intermediate-I–and intermediate-II–risk groups (176 v 8 months, respectively). For low-risk patients, the overall survival rate was more than 86% at 20 years.

CONCLUSION: According to these results, aggressive treatment approaches should rarely be recommended to younger MDS patients belonging to the low and intermediate-I risk groups.

published online ahead of print at www.jco.org on November 6, 2006.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

This article has been cited by other articles:

				D. T. Bowen, P. Fenaux, E. Hellstrom-Lindberg, and T. de Witte Time-Dependent Prognostic Scoring System for Myelodysplastic Syndromes Has Significant Limitations That May Influence Its Reproducibility and Practical Application J. Clin. Oncol., March 1, 2008; 26(7): 1180 - 1180. [Full Text] [PDF]

				L. Malcovati, U. Germing, A. Kuendgen, M. G. Della Porta, C. Pascutto, R. Invernizzi, A. Giagounidis, B. Hildebrandt, P. Bernasconi, S. Knipp, et al. Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes J. Clin. Oncol., August 10, 2007; 25(23): 3503 - 3510. [Abstract] [Full Text] [PDF]